Surgical management of hypertrophic cardiomyopathy in 2007: What is new?

World Journal of Surgery

Volumn 32, Issue 3, 2008, Pages 350-354

  Brown, Morgan L ^a   Schaff, Hartzell V ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DISOPYRAMIDE; SOTALOL; VERAPAMIL;

ALCOHOL SEPTAL ABLATION; CATHETER ABLATION; CLINICAL FEATURE; DOPPLER ECHOCARDIOGRAPHY; ECHOCARDIOGRAPHY; GENOTYPE; HEART LEFT VENTRICLE OUTFLOW TRACT; HEART LEFT VENTRICLE OUTFLOW TRACT OBSTRUCTION; HEART VENTRICLE SEPTUM; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INTERMETHOD COMPARISON; MUSCLE RESECTION; PHENOTYPE; REVIEW; SINUS NODE; TREATMENT OUTCOME;

CARDIAC SURGICAL PROCEDURES; CARDIOMYOPATHY, HYPERTROPHIC; HUMANS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 39749084563     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-007-9412-9     Document Type: Review

References (30)

1. Maron BJ, Bonow RO, Cannon RO 3rd, et al. (1987) Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med 316:780-789
2. Marian AJ, Roberts R (2001) The molecular genetic basis for hypertrophic cardiomyopathy. J Mol Cell Cardiol 33:655-670
3. Burch M, Blair E (1999) The inheritance of hypertrophic cardiomyopathy. Pediatr Cardiol 20:313-316
4. Roberts R, Sigwart U (2001) New concepts in hypertrophic cardiomyopathies, part I. Circulation 104:2113-2116
5. Watkins H, Rosenweig A, Hwang DS, et al. (1992) Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 326:1108-1114
6. Ackerman MJ, VanDriest SL, Ommen SR, et al. (2002) Prevalence and age-dependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J Am Coll Cardiol 39:2042-2048
7. Van Driest SL, Ackerman MJ, Ommen SR, et al. (2002) Prevalence and severity of "benign" mutations in the beta-myosin heavy chain, cardiac troponin T, and alpha-tropomyosin genes in hypertrophic cardiomyopathy. Circulation 106:3085-3090
8. Taylor MR, Carniel E, Mestroni L (2004) Familial hypertrophic cardiomyopathy: clinical features, molecular genetics and molecular genetic testing. Expert Rev Mol Diagn 4:99-113
9. Maron MS, Olivotto I, Zenovich AG, et al. (2006) Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 114:2232-2239
10. Maron MS, Olivotto I, Betocchi S, et al. (2003) Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 348:295-303
11. Adelman AG, Shah PM, Gramiak R, et al. (1970) Long-term propranolol therapy in muscular subaortic stenosis. Br Heart J 32:804-811
12. Epstein SE, Rosing DR (1981) Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 64:437-441
13. Bonow RO, Rosing DR, Bacharach SL, et al. (1981) Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation 64:787-796
14. Rosing DR, Condit JR, Maron BJ, et al. (1981) Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. Am J Cardiol 48:545-553
15. Sherrid MV, Bara I, McKenna WJ, et al. (2005) Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 45:1251-1258
16. Melacini P, Maron BJ, Bobbo F, et al. (2007) Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart 93:708-710
17. Fananapazir L, Epstein ND (1995) Genotype-phenotype correlations in hypertrophic cardiomyopathy. Insights provided by comparisons of kindreds with distinct and identical beta-myosin heavy chain gene mutations. Circulation 89:22-32
18. Jeanrenaud X, Goy JJ, Kappenberger L (1992) Effects of dual-chamber pacing in hypertrophic obstructive cardiomyopathy. Lancet 339:1318-1323
19. Linde C, Gadler F, Kappenberger L, et al. (1999) Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. PIC Study Group. Pacing in cardiomyopathy. Am J Cardiol 83:903-907
20. Nishimura RA, Trusty JM, Hayes DL, et al. (1997) Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol 29:435-441
21. Alam M, Dokainish H, Lakkis N (2005) Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. J Interv Cardiol 19:319-327
22. Singh M, Edwards WD, Holmes DR Jr, et al. (2001) Anatomy of the first septal perforating artery: a study with implications for ablation therapy for hypertrophic cardiomyopathy. Mayo Clin Proc 76:799-802
23. Chowdhary S, Galiwango, Woo A, et al. (2007) Inferior infarction following alcohol septal ablation: a consequence of "collateral damage"? Catheter Cardiovasc Interv 69:236-242
24. Ommen SR, Nishimura RA (2004) Hypertrophic cardiomyopathy. Curr Probl Cardiol 29:239-291
25. Ommen SR, Maron BJ, Olivotto I, et al. (2005) Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 46:470-476
26. McLeod CJ, Ommen SR, Ackerman MJ, et al. (2007) Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J 28:2583-2588
27. Spirito P, Bellone P, Harris KM, et al. (2000) Magnitude of left ventricular hypertrophy and the risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 342:1778-1785
28. Valeti US, Nishimura RA, Holmes DR, et al. (2007) Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol 49:350-357
29. Maron BJ, Dearani JA, Ommen SR, et al. (2004) The Case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 44:2044-2053
30. Holmes Dr, Valeti US, Nishimura RA (2005) Alcohol septal ablation for hypertrophic cardiomyopathy: indications and technique. Catheter Cardiovasc Interv 66:375-389